Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis (Q31017620)

28 June 2017

Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis (English)

1 reference

28 June 2017

2

Cris S Constantinescu

1 reference

28 June 2017

Simona E Constantinescu

series ordinal

1

1 reference

PubMed ID

26536299

28 June 2017

language of work or name

English

0 references

publication date

4 November 2015

1 reference

Expert Review of Clinical Pharmacology

28 June 2017

1 reference

28 June 2017

9

1 reference

28 June 2017

49-57

1 reference

28 June 2017

1

1 reference

Drug treatment of multiple sclerosis

28 June 2017

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Efficacy and safety of laquinimod in multiple sclerosis: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Cost of multiple sclerosis by level of disability: a review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Advances in the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Oral laquinimod treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1108189

10.1586/17512433.2016.1108189

21 January 2018

Identifiers

DOI

1 reference

28 June 2017

1 reference

PubMed ID

26536299